CY1121414T1 - Παρασκευη ιικου φορεα - Google Patents

Παρασκευη ιικου φορεα

Info

Publication number
CY1121414T1
CY1121414T1 CY20181100533T CY181100533T CY1121414T1 CY 1121414 T1 CY1121414 T1 CY 1121414T1 CY 20181100533 T CY20181100533 T CY 20181100533T CY 181100533 T CY181100533 T CY 181100533T CY 1121414 T1 CY1121414 T1 CY 1121414T1
Authority
CY
Cyprus
Prior art keywords
virus
modified
cell
operator
production
Prior art date
Application number
CY20181100533T
Other languages
English (en)
Inventor
Paul Michael Howley
Liang Liu
Original Assignee
Sementis Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013904242A external-priority patent/AU2013904242A0/en
Application filed by Sementis Limited filed Critical Sementis Limited
Publication of CY1121414T1 publication Critical patent/CY1121414T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151Methods of production or purification of viral material
    • C12N2710/24152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σ' ένα τροποποιημένο θηλαστικό κύτταρο όπου το γονιδίωμα του κυττάρου τροποποιείται για να περιλαμβάνει μία αλληλουχία που κωδικοποιεί το CP77 υπό τον έλεγχο ενός υποκινητή, έτσι ώστε η τροποποιημένη κυτταρική σειρά να διατηρεί τον πολλαπλασιασμό ενός ιού ευλογιάς, που να είναι λιγότερο ικανός ή ανίκανος να πολλαπλασιάζεται στο μη τροποποιημένο κύτταρο.
CY20181100533T 2013-11-01 2018-05-22 Παρασκευη ιικου φορεα CY1121414T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013904242A AU2013904242A0 (en) 2013-11-01 Viral vector manufacture
AU2014900370A AU2014900370A0 (en) 2014-02-07 Orthopox vectors and propagation
PCT/AU2014/050330 WO2015061858A1 (en) 2013-11-01 2014-11-03 Viral vector manufacture

Publications (1)

Publication Number Publication Date
CY1121414T1 true CY1121414T1 (el) 2020-05-29

Family

ID=53003022

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100533T CY1121414T1 (el) 2013-11-01 2018-05-22 Παρασκευη ιικου φορεα

Country Status (24)

Country Link
US (2) US10544397B2 (el)
EP (2) EP3375882B1 (el)
JP (2) JP6682443B2 (el)
KR (1) KR102047030B1 (el)
CN (1) CN106255758B (el)
AU (1) AU2014344738B2 (el)
CA (1) CA2931518C (el)
CY (1) CY1121414T1 (el)
DK (2) DK3063278T3 (el)
ES (1) ES2670034T3 (el)
HK (1) HK1223395A1 (el)
HR (1) HRP20180789T1 (el)
HU (1) HUE037718T2 (el)
LT (1) LT3063278T (el)
NO (1) NO3063278T3 (el)
NZ (1) NZ720241A (el)
PL (1) PL3063278T3 (el)
PT (1) PT3063278T (el)
RS (1) RS57290B1 (el)
RU (1) RU2658487C2 (el)
SG (1) SG11201603919XA (el)
SI (1) SI3063278T1 (el)
TR (1) TR201807128T4 (el)
WO (1) WO2015061858A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109862909A (zh) * 2016-08-19 2019-06-07 赛门蒂斯有限公司 病毒疫苗
JP2018081568A (ja) * 2016-11-17 2018-05-24 グローリー株式会社 紙幣収納装置および紙幣処理機
WO2024003346A1 (en) * 2022-06-30 2024-01-04 Bavarian Nordic A/S Mammalian cell line for the production of modified vaccinia virus ankara (mva)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2604183B1 (fr) * 1986-09-23 1988-12-30 Transgene Sa Sequence d'adn, vecteurs, virus recombinants et procede mettant en oeuvre des virus de la vaccine recombinants capables de se multiplier dans les cellules cho
AU694519B2 (en) 1994-04-29 1998-07-23 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
CA2489301A1 (en) * 2002-08-07 2004-02-19 Bavarian Nordic A/S Vaccinia virus host range genes to increase the titer of avipoxviruses
FR2884255B1 (fr) * 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
JP2009545309A (ja) * 2006-08-04 2009-12-24 ダブリン シティ ユニバーシティ 組換え型生物学的製剤を製造する方法

Also Published As

Publication number Publication date
EP3063278A1 (en) 2016-09-07
JP6682443B2 (ja) 2020-04-15
RU2658487C2 (ru) 2018-06-21
EP3063278A4 (en) 2017-04-12
CN106255758B (zh) 2020-06-23
AU2014344738B2 (en) 2019-03-21
RU2016121425A (ru) 2017-12-04
EP3375882B1 (en) 2019-10-16
HRP20180789T1 (hr) 2018-09-07
PT3063278T (pt) 2018-05-25
JP2020039340A (ja) 2020-03-19
DK3063278T3 (en) 2018-06-06
HUE037718T2 (hu) 2018-09-28
LT3063278T (lt) 2018-07-10
EP3375882A1 (en) 2018-09-19
JP2016534755A (ja) 2016-11-10
US20170029784A1 (en) 2017-02-02
CN106255758A (zh) 2016-12-21
RS57290B1 (sr) 2018-08-31
CA2931518C (en) 2021-03-09
DK3375882T3 (da) 2019-12-16
SG11201603919XA (en) 2016-07-28
KR102047030B1 (ko) 2019-11-20
US10544397B2 (en) 2020-01-28
EP3063278B1 (en) 2018-02-28
TR201807128T4 (tr) 2018-06-21
HK1223395A1 (zh) 2017-07-28
NO3063278T3 (el) 2018-07-28
CA2931518A1 (en) 2015-05-07
KR20160079868A (ko) 2016-07-06
US20200190482A1 (en) 2020-06-18
ES2670034T3 (es) 2018-05-29
SI3063278T1 (sl) 2019-04-30
NZ720241A (en) 2019-10-25
PL3063278T3 (pl) 2018-08-31
AU2014344738A1 (en) 2016-06-09
WO2015061858A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
CY1122833T1 (el) Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7
PH12018501159A1 (en) Composition and methods for immunooncology
MY195167A (en) Modified Nucleotide Linkers
PH12017500858A1 (en) Mocrocyclic peptides useful as immunomodulators
UY34820A (es) Compuestos tipo pirrolo-pirrolidinona
PH12019502171A1 (en) Composition and methods for immunooncology
PE20151433A1 (es) Nucleosidos sustituidos, nucleotidos y analogos de los mismos
UY34824A (es) Nucleósidos de espirooxetano de uracilo
BR112016029076A2 (pt) modulação de atividade de complemento
MX2022013454A (es) Moduladores de la actividad del complemento.
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
CY1121414T1 (el) Παρασκευη ιικου φορεα
BR112018005940A2 (pt) métodos de garantia da qualidade molecular para uso em sequenciamento
TR201902604T4 (tr) Fi̇berglas kompozi̇ti̇, bunun cam fi̇beri̇ ve bunun kompozi̇t materyali̇.
BR112017020896A2 (pt) variantes de protoxina-ii e métodos de uso
NZ764154A (en) New cath2 derivatives
MA42373A (fr) Procede de liaison de dioxyde de carbone
PH12018500155A1 (en) Recombinant orf virus vector
PH12020551126A1 (en) Modulation of heparin-binding epidermal growth factor activity for tympanic membrane healing
PH12016500683B1 (en) Synthetic route to 2`-deoxy-2`,2`-difluorotetrahydrouridines
SA516371722B1 (ar) عملية لانتاج مطاط بيوتيل معدل
BR112016027455A2 (pt) moduladores ppar
TR201904143T4 (tr) Silillenmiş poliüretanlar.
MY187959A (en) Reactor
UY34802A (es) ?suspensión acuosa que contiene polímeros adsorbibles sostenibles, un proceso para prepararla y su uso?.